Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cell Mol Biol (Noisy-le-grand) ; 70(2): 183-188, 2024 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-38430023

RESUMEN

This study aimed to elucidate the effect of mitochondria-targeted reactive oxygen species (ROS) blockor SS-31 on hepatic stellate cells (HSC) activation during liver fibrosis. TGF-ß1 was employed to induce HSC activation, while MitoSOX Red was utilized to assess the presence of mitochondrial ROS. The mitochondrial membrane potential (MMP) was measured using the JC-1 probe, and the ATP level was determined using a specific kit. The proliferation of HSCs was assessed using CCK-8 and colony formation assays, whereas flow cytometry was employed to detect HSC apoptosis. Fibrotic markers (COL1A1 and α-SMA) and NLRP3 inflammasome components (NLRP3, caspase-1, and ASC) were analyzed via Western blotting. Liver fibrosis was induced in mice using CCl4, and subsequently, histopathological changes were observed through HE staining and Masson staining. In TGF-ß1-activated HSCs, mitochondrial ROS expression increased, MMP and ATP content decreased, indicating mitochondrial damage. After TGF-ß1 induction, HSC proliferation increased, apoptosis decreased, and COL1A1, α-SMA, and NLRP3 inflammasome protein expression increased. After SS-31 treatment, mitochondrial ROS expression decreased, MMP recovered, ATP level increased, HSC proliferation decreased, apoptosis increased, and the expressions of COL1A1, α-SMA, and NLRP3 inflammasome decreased. NLRP3 blockor MCC950 treatment blocked HSC activation. CCL4-induced liver fibrosis mice had inflammatory cell infiltration and significant collagen fiber deposition in the liver. After SS-31 treatment, liver inflammation and collagen deposition were significantly reduced. SS-31, as a mitochondria-targeted ROS blockor, can block HSC activation by regulating the NLRP3 inflammasome, thereby alleviating liver fibrosis.


Asunto(s)
Células Estrelladas Hepáticas , Inflamasomas , Proteína con Dominio Pirina 3 de la Familia NLR , Animales , Ratones , Adenosina Trifosfato/metabolismo , Colágeno/metabolismo , Células Estrelladas Hepáticas/efectos de los fármacos , Células Estrelladas Hepáticas/metabolismo , Inflamasomas/efectos de los fármacos , Inflamasomas/metabolismo , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Mitocondrias/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/efectos de los fármacos , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo
2.
Cancer Cell Int ; 20: 193, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32508529

RESUMEN

BACKGROUND: Gastric cancer (GC) remains one of the most common digestive malignancies worldwide and ranked third causes of cancer-related death. Mounting evidence has revealed that miRNAs exert critical regulatory roles in GC development. METHODS: Immunohistochemistry (IHC) and western blot assay were performed to determine the protein expression levels of neuropilin-1 (NRP1) and mRNA levels were confirmed by quantitative RT-PCR (qRT-PCR) in GC tissues. Kaplan-Meier analysis was performed to evaluate the prognostic value of NRP1 in GC. Knockdown of NRP1 was conducted to analyse its function in vitro and vivo. Luciferase reporter assay, western blot and qRT-qPCR were employed to identify the miRNAs which directly targeted NRP1. Furthermore, Bioinformatics analysis and experimental verification were used to explore the potential molecular mechanism and signalling pathway. RESULTS: In the current study, we revealed that NRP1 was highly expressed in GC tumor tissues and was associated with poor prognosis in GC patients. NRP1 knockdown inhibited GC cell growth, migration and invasion in vitro, while suppressed GC xenograft tumor development in vivo. Bioinformatics analysis predicted that miR-19b-3p down-regulated NRP1 expression by targeting its 3'-UTR. Functional assay demonstrated that miR-19b-3p inhibited GC cell growth, migration and invasion via negatively regulating NRP1. Overexpression NRP1 partially reversed the regulatory effect of miR-19b-3p. Moreover, we showed that miR-19b-3p/NRP1 axis regulated the epithelial-to-mesenchymal transition and focal adhesion in GC, which might contribute the GC development and progression. CONCLUSIONS: Taken together, our findings suggest a regulatory network of miR-19b-3p/NRP1 in GC development. The miR-19b-3p/NRP1 axis might be further explored as a potential diagnostic and therapeutic target in GC.

3.
Cell Physiol Biochem ; 44(3): 1038-1050, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29179214

RESUMEN

BACKGROUND/AIMS: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor. This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune system is incompletely understood. METHODS: The immune influence of cetuximab therapy in CRC patients was investigated by analyzing peripheral blood mononuclear cells using flow cytometry. We undertook in vitro cytotoxicity and cytokine-profile assays to ascertain the immunomodulatory effect of cetuximab treatment. RESULTS: The number of CD3+ T, CD8+ T, and natural killer (NK) cells was increased significantly and T-regulatory cells reduced gradually after cetuximab treatment. Percentage of CD4+ T, natural killer T (NKT)-like, invariant NKT, and dendritic cells was similar between baseline patients and cetuximab patients. Expression of CD137 on NK and CD8+ T cells was increased significantly after 4 weeks of cetuximab therapy. In vitro cetuximab treatment markedly increased expression of CD137 and CD107a on NK and CD8+ T cells. Cetuximab treatment promoted the cytotoxic activity of NK and CD8+ T cells against tumor cells. CONCLUSION: Cetuximab treatment promotes activation of the immune response but alleviates immunosuppression: this might be the underlying anti-CRC effect of cetuximab.


Asunto(s)
Antineoplásicos Inmunológicos/uso terapéutico , Cetuximab/uso terapéutico , Neoplasias Colorrectales/tratamiento farmacológico , Linfocitos/inmunología , Adulto , Anciano , Antineoplásicos Inmunológicos/farmacología , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/metabolismo , Células Cultivadas , Cetuximab/farmacología , Neoplasias Colorrectales/patología , Citocinas/sangre , Femenino , Células HT29 , Humanos , Células K562 , Células Asesinas Naturales/citología , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/metabolismo , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Linfocitos/citología , Linfocitos/efectos de los fármacos , Proteína 1 de la Membrana Asociada a los Lisosomas/metabolismo , Masculino , Persona de Mediana Edad , Linfocitos T Reguladores/citología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/metabolismo , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/metabolismo
4.
Biomed Res Int ; 2017: 6484835, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28913356

RESUMEN

BACKGROUND: MicroRNAs (miRNAs) may serve as potential molecular markers to predict liver injury resulting from chronic hepatitis B (CHB). In the present study, we want to study the expression profile and clinical significance of miRNAs at different stages of CHB virus infection. METHODS: Using miRNA microarray, we investigated the global expression profiles of cellular miRNA in asymptomatic hepatitis B antigen carriers (ASCs) and CHB patients, compared with healthy controls (HCs). RESULTS: We identified 79 and 203 differentially expressed miRNAs in the peripheral blood mononuclear cells of ASCs and CHB patients compared to HCs, respectively. Some of these miRNAs were common to ASCs and CHB patients, but another set of miRNAs that showed differential expression between ASCs and CHB patients was also identified. Gene ontology and pathway enrichment analysis showed that the target genes of the identified miRNAs played a role in important biological functions, such as learning or memory, cell-cell adherens junction, ion channel inhibitor activity, TGF-beta signaling pathway, and p53 signaling pathway. CONCLUSION: We identified some significant differentially expressed miRNA in different phases of HBV infection, which might serve as biomarkers or therapeutic targets in the future.


Asunto(s)
Biomarcadores/metabolismo , Portador Sano/metabolismo , Antígenos de Superficie de la Hepatitis B/genética , Hepatitis B Crónica/genética , Hepatitis B Crónica/metabolismo , MicroARNs/genética , Adulto , Anciano , Portador Sano/virología , Femenino , Perfilación de la Expresión Génica/métodos , Ontología de Genes , Virus de la Hepatitis B/fisiología , Humanos , Leucocitos Mononucleares/metabolismo , Hígado/metabolismo , Hígado/virología , Masculino , Persona de Mediana Edad , Factor de Crecimiento Transformador beta/genética
5.
Sci Rep ; 7(1): 796, 2017 04 11.
Artículo en Inglés | MEDLINE | ID: mdl-28400582

RESUMEN

Serum anti-mitochondrial antibody type 2 (AMA-M2) is considered as a pivotal biomarker for the diagnosis of primary biliary cholangitis (PBC). However, serological tests have many limitations, including inconvenience, invasiveness, and infection risks. Thus, a less invasive approach to detect AMA-M2 titer is desirable. We examined salivary AMA-M2 of potential PBC patients and found that AMA-M2 could be detected only in saliva of serum AMA-M2-positive PBC patients, but not in saliva of serum AMA-M2-negative PBC patients, oral lichen planus patients (OLP) patients, or healthy controls. Furthermore, the concentration of salivary AMA-M2 was positively correlated with the amount of serum AMA-M2 in patients. The salivary inflammatory cytokines were increased in the PBC, consistent with the results of serum test. These findings indicated that saliva might be a less invasive and cost-effective medium to accurately test for AMA-M2 levels and this is a promising development for the diagnosis and monitoring of PBC.


Asunto(s)
Autoanticuerpos/inmunología , Biomarcadores , Cirrosis Hepática Biliar/diagnóstico , Cirrosis Hepática Biliar/inmunología , Mitocondrias/inmunología , Saliva/inmunología , Autoanticuerpos/metabolismo , Autoantígenos , Citocinas/metabolismo , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Cirrosis Hepática Biliar/metabolismo , Pruebas de Función Hepática , Curva ROC , Saliva/metabolismo
6.
Oncotarget ; 8(65): 108406-108417, 2017 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-29312539

RESUMEN

Regulatory T cells (Tregs) play an indispensable role in the progression of primary biliary cholangitis (PBC). Although Tregs could normalize costimulation in in vivo and in vitro models, it is obscure whether and how Tregs mediate these effects in PBC. Herein we focused on the quantitative and functional characteristics of Tregs in PBC. The number and proportion of Tregs, and the production of interleukin (IL)-10 were all significantly less in the PBC patients than in the healthy controls (HCs). In addition, compared to the HCs, the costimulatory CD86 of the circulation and liver were significantly higher in the patients with PBC. CD86 expression on CD1c+ cells negatively correlated with the proportion of Tregs. There was also a positive correlation between mayo risk score and the ratio of CD86/Treg. In vitro experiments showed that inhibition of CD86 expression on CD1c+ cells by Tregs was significantly weakened in the PBC patients. Furthermore, the autoantibodies from the PBC patients could promote CD86 expression on CD1c+ cells and transforming growth factor-ß production by human hepatic stellate cells. Overall, Tregs declined in inhibition on co-stimulation expression in the presence of autoantibodies, which could be associated to PBC-related bile duct injury and fibrosis. This indicated that maintenance of balance of co-stimulation and Tregs could be beneficial for PBC.

7.
Oncotarget ; 8(1): 70-82, 2017 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-27926535

RESUMEN

This study focuses on characterizing the effect of a high salt diet (HSD) on intestinal immunity and the risk of inflammatory bowel diseases (IBD). We found that mice on a HSD had an increased frequency of IL-17A producing cells in the intestinal lamina propria (LP) compared to mice on a normal diet (ND). Furthermore, most intestinal IL-17A producing cells were CD4+TCRß+ cells. A HSD increased the LP T helper 17 (Th17) responses in both the small and large intestines but did not increase the Th17 response of other gut-associated lymphoid organ. Although, HSD did not change the percentage of regulatory T (Treg) cells, HSD significantly inhibit secretion of IL-10 and the suppressive function of Treg cells. Moreover, we found that HSD exacerbates trinitrobenzenesulfonic acid (TNBS) induced colitis, and Th17 response was significantly increased in the colonic LP of HSD TNBS-treated mice compared with the ND TNBS-treated mice. This study demonstrates that HSD stimulates the intestinal Th17 response but inhibits the function of Treg cells. Moreover, HSD exacerbates TNBS induced mice colitis, suggesting that HSD disrupts the intestinal immunity and increases the risk of IBD.


Asunto(s)
Colitis/etiología , Dieta , Mucosa Intestinal/inmunología , Células T Invariantes Asociadas a Mucosa/inmunología , Sodio en la Dieta , Células Th17/inmunología , Animales , Colitis/metabolismo , Colitis/patología , Dieta/efectos adversos , Modelos Animales de Enfermedad , Enfermedades Inflamatorias del Intestino/etiología , Enfermedades Inflamatorias del Intestino/metabolismo , Enfermedades Inflamatorias del Intestino/patología , Interleucina-17/biosíntesis , Mucosa Intestinal/metabolismo , Masculino , Ratones , Células T Invariantes Asociadas a Mucosa/metabolismo , Sodio en la Dieta/efectos adversos , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Células TH1/inmunología , Células TH1/metabolismo , Células Th17/metabolismo , Ácido Trinitrobencenosulfónico/efectos adversos
8.
Sci Rep ; 6: 36365, 2016 11 08.
Artículo en Inglés | MEDLINE | ID: mdl-27821872

RESUMEN

Glycolipids are potent activator of natural killer T (NKT) cells. The relationship between NKT cells and intestinal bacterial glycolipids in liver disorders remained unclear. We found that, in sharp contrast to specific pathogen-free (SPF) mice, germ-free (GF) mice are resistant to Concanavalin A (ConA)-induced liver injury. ConA treatment failed to trigger the activation of hepatic NKT cells in GF mice. These defects correlated with the sharply reduced levels of CD1d-presented glycolipid antigens in ConA-treated GF mice compared with SPF counterparts. Nevertheless, CD1d expression was similar between these two kinds of mice. The absence of intestinal bacteria did not affect the incidence of αGalCer-induced liver injury in GF mice. Importantly, we found the intestinal bacteria contain glycolipids which can be presented by CD1d and recognized by NKT cells. Furthermore, supplement of killed intestinal bacteria was able to restore ConA-mediated NKT cell activation and liver injury in GF mice. Our results suggest that glycolipid antigens derived from intestinal commensal bacteria are important hepatic NKT cell agonist and these antigens are required for the activation of NKT cells during ConA-induced liver injury. These finding provide a mechanistic explanation for the capacity of intestinal microflora to control liver inflammation.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/inmunología , Concanavalina A/efectos adversos , Glucolípidos/inmunología , Células T Asesinas Naturales/metabolismo , Animales , Antígenos CD1d/metabolismo , Proteínas Bacterianas/inmunología , Modelos Animales de Enfermedad , Microbioma Gastrointestinal , Vida Libre de Gérmenes , Intestinos/microbiología , Ratones , Células T Asesinas Naturales/efectos de los fármacos , Organismos Libres de Patógenos Específicos
9.
Medicine (Baltimore) ; 95(5): e2606, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26844470

RESUMEN

Human infection with avian influenza A virus (H7N9) is a concern because of the mortality rate. Previously, we characterized immunological responses during active infection with it and reported evidence of impaired antigen-presenting capability, particularly in severely affected individuals. Here we describe an investigation of immunological responses during a 1-year follow-up of survivors of H7N9 infection. Survivors of H7N9 infection were classified as having had mild (n = 42) or severe infection (n = 26). Their immune status, including human leukocyte antigen-DR expression on monocytes, and their ability to mount cytokine responses were assessed at 1, 3, and 12 months postinfection.The total lymphocyte count and the percentages of different types of lymphocytes had normalized by 1 month postinfection. However, there was evidence of ongoing impairment of immune responses in those who had had severe infection. This included reduced human leukocyte antigen-DR expression on CD14 monocytes, reduced interferon-γ production by T cells, and higher plasma levels of the matrix metalloproteinases 2, 3, and 9. By 3 months postinfection, these had all normalized.After severe H7N9 infection, recovery of the antigen-presenting capability of monocytes and T-cell responses are delayed. This may lead to an increased vulnerability to secondary bacterial infections.


Asunto(s)
Presentación de Antígeno , Subtipo H7N9 del Virus de la Influenza A/inmunología , Gripe Humana/inmunología , Sobrevivientes , Adulto , Anciano , Citocinas/metabolismo , Femenino , Estudios de Seguimiento , Antígenos HLA-DR/metabolismo , Humanos , Gripe Humana/patología , Interferón gamma/biosíntesis , Recuento de Linfocitos , Masculino , Metaloproteinasas de la Matriz/sangre , Persona de Mediana Edad , Monocitos/inmunología , Linfocitos T/metabolismo , Factores de Tiempo
11.
Cell Physiol Biochem ; 37(5): 1983-96, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26584297

RESUMEN

BACKGROUND/AIMS: Osteopontin (OPN) expression is increased during the course of various chronic inflammatory diseases, including tuberculosis (TB). However, its prognostic value in TB management remains unclear. This study aimed to determine whether OPN could associate with other cytokines serving as a reliable biomarker for evaluating the effectiveness of early anti-TB treatments. METHODS: Smear-positive pulmonary TB patients (n = 20) were recruited, and the plasma levels of OPN, IP-10, TNF-α, and IL-12 were measured by ELISA before initiation of anti-TB therapy and after sputum smear conversion. The C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR) were also tracked during anti-TB treatment. RESULTS: OPN expression was significantly elevated in patients with smear-positive pulmonary TB, and was closely related with disease severity. Monitoring during the treatment course revealed that its expression, along with that of IFN-x03B3;-induced protein 10 (IP-10), decreased significantly only after sputum smear conversion. Moreover, OPN levels positively correlated with CRP levels before and after anti-TB treatment. Furthermore, OPN markedly promoted IP-10 expression in peripheral blood mononuclear cells. CONCLUSION: Association between OPN and IP-10 may serve as a reliable prognostic indicator for improvement during the early treatment of pulmonary TB, and may help clinicians in tailoring an effective TB treatment regimen.


Asunto(s)
Quimiocina CXCL10/sangre , Osteopontina/sangre , Tuberculosis Pulmonar/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antituberculosos/farmacología , Sedimentación Sanguínea , Proteína C-Reactiva/análisis , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Interleucina-12/sangre , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Masculino , Persona de Mediana Edad , Pronóstico , Índice de Severidad de la Enfermedad , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/metabolismo , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
12.
Cell Physiol Biochem ; 37(2): 735-46, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26356264

RESUMEN

BACKGROUND/AIMS: Regular physical exercise can enhance resistance to many microbial infections. However, little is known about the mechanism underlying the changes in the immune system induced by regular exercise. METHODS: We recruited members of a university badminton club as the regular exercise (RE) group and healthy sedentary students as the sedentary control (SC) group. We investigated the distribution of peripheral blood mononuclear cell (PBMC) subsets and functions in the two groups. RESULTS: There were no significant differences in plasma cytokine levels between the RE and SC groups in the true resting state. However, enhanced levels of IFN-γ, TNF-α, IL-6, IFN-α and IL-12 were secreted by PBMCs in the RE group following microbial antigen stimulation, when compared to the SC group. In contrast, the levels of TNF-α and IL-6 secreted by PBMC in the RE group were suppressed compared with those in SC group following non-microbial antigen stimulation (concanavalin A or α-galactosylceramide). Furthermore, PBMC expression of TLR2, TLR7 and MyD88 was significantly increased in the RE group in response to microbial antigen stimulation. CONCLUSION: Regular exercise enhances immune cell activation in response to pathogenic stimulation leading to enhanced cytokine production mediated via the TLR signaling pathways.


Asunto(s)
Citocinas/sangre , Ejercicio Físico/fisiología , Antígenos del Núcleo de la Hepatitis B/inmunología , Streptococcus pyogenes/inmunología , Receptores Toll-Like/metabolismo , Concanavalina A/inmunología , Citocinas/genética , Femenino , Galactosilceramidas/inmunología , Humanos , Masculino , Conducta Sedentaria , Transducción de Señal , Receptores Toll-Like/genética , Regulación hacia Arriba , Adulto Joven
13.
Drug Des Devel Ther ; 9: 3003-16, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26109844

RESUMEN

PURPOSE: Dendritic cells (DCs) play critical roles in promoting innate and adaptive immunity in microbial infection. Functional impairment of DCs may mediate the suppression of viral-specific T-cell immune response in chronic hepatitis B (CHB) patients. Osteopontin (OPN) is involved in several liver diseases and infectious diseases. However, whether OPN affects DC function in hepatitis B virus (HBV) infection is unknown. METHODS: Twenty CHB patients and 20 healthy volunteers were recruited. OPN secreted by DCs was compared. Peripheral blood mononuclear cells cultured with OPN antibody were examined to study the costimulatory molecular expression and interleukin (IL)-12 production of DCs after HBV antigenic stimulation. OPN-deficient mice were used to investigate the influence of OPN on DC maturation and function after HBV antigenic stimulation in vitro and in vivo. Exogenous OPN was administrated to further verify the functioning of DCs from CHB patients upon HBV antigenic stimulation. RESULTS: We found that OPN production of DCs from CHB patients was significantly lower than those from healthy volunteers. The absence of OPN impaired IL-12 production and costimulatory molecular expression of DCs upon stimulation with HBV antigens. Defective DC function led to reduced activation of Th1 response to HBV antigens. In addition, OPN deficiency in DCs reduced the HBV antigen-induced inflammatory response in the liver of mice. Importantly, OPN administration significantly promoted the maturation of DCs from CHB patients in vitro. CONCLUSION: These findings suggested that OPN could improve the maturation and functioning of DCs in the immune response to HBV antigens, which might be useful to further improve the effect of DC vaccine.


Asunto(s)
Células Dendríticas/efectos de los fármacos , Antígenos de la Hepatitis B/farmacología , Osteopontina/genética , Osteopontina/uso terapéutico , Traslado Adoptivo , Adulto , Animales , Células de la Médula Ósea/efectos de los fármacos , Antígeno CD11c/metabolismo , Técnicas de Cocultivo , Células Dendríticas/patología , Femenino , Antígenos e de la Hepatitis B/sangre , Hepatitis C/tratamiento farmacológico , Hepatitis C/patología , Humanos , Interleucina-12/biosíntesis , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Monocitos/efectos de los fármacos , Monocitos/inmunología , Células TH1/efectos de los fármacos , Células TH1/inmunología
14.
Jpn J Infect Dis ; 68(6): 467-73, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25866117

RESUMEN

The level of osteopontin (OPN) increases during bacterial lung infection. However, the OPN level in virus-induced lung injury is unclear, and the relationship between the hyer-production of OPN and lung injury remains to be thoroughly understood. Therefore, we sought to determine whether a relationship exists between OPN and pulmonary damage. Particularly, pulmonary edema and the destruction of pulmonary tissue. In this study, we found that the OPN level was significantly elevated in patients with pulmonary damage, and there was a positive correlation between the OPN serum level and disease severity in influenza lung injury. The epithelial sodium channel (ENaC) is the main mechanism of clearance of pulmonary edema fluid, and matrix metalloproteinase 7 (MMP7) can degrade the extracellular matrix. In lung epithelial cells, OPN markedly decreased the mRNA expression of the α-subunit of ENaC through integrin ß3 and CD44 (OPN receptors); however, the expression of MMP7 was promoted by OPN interaction with integrin ß1 and CD44. In addition, OPN increased the levels of tumor necrosis factor-α and interleukin-6. These findings suggested that OPN might increase influenza virus-induced lung injury by augmenting lung epithelial cell apoptosis and impairing ENaC and extracellular matrix destruction.


Asunto(s)
Gripe Humana/patología , Lesión Pulmonar/patología , Osteopontina/sangre , Índice de Severidad de la Enfermedad , Adulto , Anciano , Anciano de 80 o más Años , Células Epiteliales/efectos de los fármacos , Células Epiteliales/fisiología , Canales Epiteliales de Sodio/metabolismo , Matriz Extracelular/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad
15.
Sci Rep ; 4: 7259, 2014 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-25435303

RESUMEN

Gut microbiota are implicated in many liver diseases. Concanavalin A (ConA)-induced hepatitis is a well-characterized murine model of fulminant immunological hepatic injury. Oral administration of pathogenic bacteria or gentamycin to the mice before ConA injection, liver injury and lymphocyte distribution in liver and intestine were assessed. Our data show that administration of pathogenic bacteria exacerbated the liver damage. There was more downregulation of activation-induced natural killer T (NKT) cells in the liver of pathogenic bacteria-treated ConA groups. Also, there was a negative correlation between the numbers of hepatic NKT cells and liver injury in our experiments. Moreover, intestinal dendritic cells (DCs) were increased in pathogenic bacteria-treated ConA groups. The activation of DCs in Peyer's patches and the liver was similar to the intestine. However, depletion of gut gram-negative bacteria alleviated ConA-induced liver injury, through suppressed hepatic NKT cells activation and DCs homing in liver and intestine. In vitro experiments revealed that DCs promoted NKT cell cytotoxicity against hepatocyte following stimulation with pathogenic bacteria. Our study suggests that increased intestinal pathogenic bacteria facilitate immune-mediated liver injury, which may be due to the activation of NKT cells that mediated by intestinal bacterial antigens activated DCs.


Asunto(s)
Hepatitis/inmunología , Hepatitis/prevención & control , Intestinos/inmunología , Microbiota/inmunología , Células T Asesinas Naturales/inmunología , Probióticos/uso terapéutico , Animales , Células Dendríticas/inmunología , Células Dendríticas/patología , Femenino , Hepatitis/patología , Inmunomodulación/inmunología , Intestinos/patología , Ratones , Ratones Endogámicos C57BL , Modelos Inmunológicos , Resultado del Tratamiento
16.
Immunol Lett ; 160(1): 65-71, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24718278

RESUMEN

Natural killer T-like (NKT-like) cells are a source of different pro-inflammatory cytokines and therefore may be involved in inflammatory processes. However, little is known about NKT-like cells during antiviral therapy. In this study, we observed significantly higher numbers of CD3(+)CD56(+) cells in patients with chronic hepatitis B (CHB) than healthy controls. Importantly, CD3(+)CD56(+) NKT-like cells markedly decreased during telbivudine treatment in patients with CHB, and a positive correlation between NKT-like cell frequency and the serum HBV DNA level was observed during early antiviral therapy. Interestingly, NKT-like cell frequency significantly reduced in well-responders at week 12 of telbivudine therapy compared to baseline, but did not significantly change in non-responders after treatment. Previous studies have shown that interleukin (IL)-17 plays a role in the pathogenesis of CHB. Serum IL-17 levels reduced significantly during early antiviral therapy, however, interferon (IFN)-γ, IL-6 and tumor necrosis factor (TNF)-α levels did not change significantly. A positive correlation was observed between the NKT-like cell frequency and serum IL-17 level in CHB patients, and NKT-like cells isolated from patients with CHB secreted substantial amounts of IL-17 in vitro. These results suggest that the NKT-like cell frequency may be one of useful immunologic marker for evaluating the efficacy of anti-HBV therapy, and that NKT-like cells are also an important source of IL-17 (in addition to conventional T cells) in patients with CHB.


Asunto(s)
Antivirales/uso terapéutico , Virus de la Hepatitis B/inmunología , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/inmunología , Células T Asesinas Naturales/inmunología , Timidina/análogos & derivados , Adulto , Femenino , Hepatitis B Crónica/virología , Humanos , Inmunofenotipificación , Interleucina-17/biosíntesis , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Células T Asesinas Naturales/efectos de los fármacos , Células T Asesinas Naturales/metabolismo , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismo , Telbivudina , Timidina/uso terapéutico , Resultado del Tratamiento , Carga Viral , Adulto Joven
17.
PLoS One ; 9(3): e92823, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24664315

RESUMEN

The outbreak of H7N9 human infection has caused concern worldwide, but the immunological characteristics of infected patients and the determinants of diverse outcomes remain to be thoroughly understood. In this study, twenty-three patients with H7N9 infections were classified into severe and mild cases. We found that severe patients were commonly lymphopenic with significantly lower levels of T cells, monocytes and related cytokine levels compared to the mild cases. The expression of HLA-DR on CD14+ cells were significantly lower in the severe infection group compared to the mild group (in acute phase: 34.65±4.88 vs. 10.37±1.69, p<0.001). Importantly, the expression of HLA-DR on CD14+ cells was negatively correlated with H7N9 infection severity. Furthermore, although the phagocytosis capabilities of monocyte were similar between two groups, the monocytes of severe infection patients had a lower antigen-presenting capacity. And some in vitro experiments suggested that the impaired antigen-presenting function is associated with lower activation of T cells in responses to immune stimulation. Our present study suggested that the severe H7N9 patients were in a state of immune decrease which presented with general lymphopenia and low antigen-presenting capacity resulting in impaired T cell response. Additionally, HLA-DR levels of CD14+ cells may be a potential biomarker for predicting H7N9 disease progression.


Asunto(s)
Presentación de Antígeno , Células Presentadoras de Antígenos/inmunología , Subtipo H7N9 del Virus de la Influenza A/inmunología , Gripe Humana/inmunología , Receptores de Lipopolisacáridos/inmunología , Linfocitos T/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Células Presentadoras de Antígenos/patología , Femenino , Antígenos HLA-DR/inmunología , Humanos , Gripe Humana/patología , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Linfocitos T/patología
18.
World J Gastroenterol ; 19(30): 4867-76, 2013 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-23946591

RESUMEN

Hepatitis B virus (HBV) infection is a global public health problem that causes persistent liver diseases such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. A large amount of people die annually from HBV infection. However, the pathogenesises of the HBV-related diseases are ill defined and the therapeutic strategies for the diseases are less than optimum. The recently discovered microRNAs (miRNAs) are tiny noncoding RNAs that regulate gene expression primarily at the post-transcriptional level by binding to mRNAs. miRNAs contribute to a variety of physiological and pathological processes. A number of miRNAs have been found to play a pivotal role in the host-virus interaction including host-HBV interaction. Numerous studies have indicated that HBV infection could change the cellular miRNA expression patterns and different stages of HBV associated disease have displayed distinctive miRNA profiles. Furthermore, the differential expressed miRNAs have been found involved in the progression of HBV-related diseases, for instance some miRNAs are involved in liver tumorigenesis and tumor metastasis. Studies have also shown that the circulating miRNA in serum or plasma might be a very useful biomarker for the diagnosis and prognosis of HBV-related diseases. In addition, miRNA-based therapy strategies have attracted increasing attention, indicating a promising future in the treatment of HBV-related diseases.


Asunto(s)
Virus de la Hepatitis B/patogenicidad , Hepatitis B Crónica/genética , MicroARNs/metabolismo , Animales , Progresión de la Enfermedad , Regulación de la Expresión Génica , Marcadores Genéticos , Terapia Genética , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/terapia , Hepatitis B Crónica/virología , Interacciones Huésped-Patógeno , Humanos , MicroARNs/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...